Sennoun Nacira, Meziani Ferhat, Dessebe Olivier, Cattan Valérie, Collin Solène, Montemont Chantal, Gibot Sebastien, Asfar Pierre, Ramaroson Andriantsitohaina, Regnault Veronique, Slama Michel, Lecompte Thomas, Lacolley Patrick, Levy Bruno
Groupe CHOC, Equipe AVENIR Inserm, Nancy Université, Faculté de Médecine, 54500 Vandoeuvre les Nancy, France.
Crit Care Med. 2009 Jan;37(1):246-55. doi: 10.1097/CCM.0b013e318192fe4f.
Recombinant human activated Protein C (APC) is used as an adjunctive therapeutic treatment in septic shock. APC seemingly acts on coagulation-inflammation interaction but also by decreasing proinflammatory gene activity, thus inhibiting subsequent production of proinflammatory cytokines, NO and NO-induced mediators, reactive oxygen species production and leukocyte-endothelium interaction. The hemodynamic effects of APC on arterial pressure and cardiac function are now well established in animal models. However, the specific effects of APC on heart and vessels have never been studied.
To investigate the potential protective properties of therapeutic ranges of APC on a rat endotoxic shock model in terms of anti-inflammatory and cytoprotective pathways.
Laboratory investigation.
University medical center research laboratory.
Rats were exposed to lipopolysaccharide (LPS) (10 mg/Kg intravenous). Endotoxic shock was treated with infusion of saline with or without APC (33 microg/kg/h) during 4 hrs. Hemodynamic parameters were continuously assessed and measurements of muscle oxygen partial pressures, NO and superoxide anion (O2(-)) by spin trapping, of NF-kappaB, metalloproteinase-9 (MMP-9) and inducible NO synthase (iNOS) by Western blotting, as well as leukocyte infiltration and MMP-9 activity were performed at both the heart and aorta level (tissue).
APC partially prevented the reduction of blood pressure induced by LPS and improved both vascular hyporeactivity and myocardial performance. This was associated with a decreased up-regulation of NF-kappaB, iNOS and MMP-9. LPS-induced tissue increases in NO and O2(-) production were decreased by APC. Furthermore, APC decreased tissue leukocyte infiltration/activation as assessed by a decrease in myeloperoxidase and matrix metalloproteinase 9 activity.
These data suggest that APC improves cardiovascular function: 1) by modulating the endotoxin induced-proinflammatory/prooxidant state, 2) by decreasing endothelial/leukocyte interaction and 3) by favoring stabilization of the extracellular matrix.
重组人活化蛋白C(APC)用于脓毒性休克的辅助治疗。APC似乎作用于凝血-炎症相互作用,还通过降低促炎基因活性,从而抑制随后促炎细胞因子、一氧化氮(NO)及NO诱导介质的产生、活性氧的产生以及白细胞-内皮细胞相互作用。APC对动脉血压和心脏功能的血流动力学效应在动物模型中已得到充分证实。然而,APC对心脏和血管的具体作用从未被研究过。
在大鼠内毒素休克模型中,从抗炎和细胞保护途径方面研究治疗剂量的APC的潜在保护特性。
实验室研究。
大学医学中心研究实验室。
大鼠静脉注射脂多糖(LPS)(10mg/kg)。在4小时内,对内毒素休克大鼠输注含或不含APC(33μg/kg/h)的生理盐水进行治疗。连续评估血流动力学参数,并通过自旋捕捉法测量肌肉氧分压、NO和超氧阴离子(O2(-)),通过蛋白质印迹法检测心脏和主动脉水平(组织)的核因子κB(NF-κB)、基质金属蛋白酶-9(MMP-9)和诱导型一氧化氮合酶(iNOS),以及进行白细胞浸润和MMP-9活性检测。
APC部分预防了LPS诱导的血压降低,并改善了血管反应性降低和心肌功能。这与NF-κB、iNOS和MMP-9上调减少有关。APC降低了LPS诱导的组织中NO和O2(-)的产生增加。此外,通过髓过氧化物酶和基质金属蛋白酶9活性降低评估,APC减少了组织白细胞浸润/活化。
这些数据表明,APC改善心血管功能的机制为:1)调节内毒素诱导的促炎/促氧化状态;2)减少内皮细胞/白细胞相互作用;3)促进细胞外基质的稳定。